Synergy Pharmaceuticals, Inc Common Stock
SGYP
SGYP was delisted on the 7th of March, 2019.
136 hedge funds and large institutions have $170M invested in Synergy Pharmaceuticals, Inc Common Stock in 2018 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 41 increasing their positions, 33 reducing their positions, and 26 closing their positions.
24% more repeat investments, than reductions
Existing positions increased: 41 | Existing positions reduced: 33
7% less funds holding
Funds holding: 147 → 136 (-11)
16% less capital invested
Capital invested by funds: $202M → $170M (-$31.8M)
38% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 26
39% less call options, than puts
Call options by funds: $3.39M | Put options by funds: $5.54M
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$875K |
| 2 |
BlackRock
New York
|
+$803K |
| 3 |
VEA
Virtus ETF Advisers
New York
|
+$763K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$720K |
| 5 |
Group One Trading
Chicago,
Illinois
|
+$563K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$12.4M |
| 2 |
CH
CVI Holdings
Wilmington,
Delaware
|
-$3.23M |
| 3 |
IBT
International Biotechnology Trust
London,
United Kingdom
|
-$2.73M |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$1.95M |
| 5 |
Morgan Stanley
New York
|
-$1.66M |
SGYP Hedge Fund Activity: Q2 2018 in Review
136 of the 4,385 institutional investors tracked by Wall St. Rank reported a position in Synergy Pharmaceuticals, Inc Common Stock (SGYP) for Q2 2018, worth a combined $170M — down 16% from $202M a quarter earlier.
Sellers outnumbered buyers: 26 funds closed out of SGYP and 16 opened new positions — a net loss of 10 holders — while 33 trimmed existing stakes and 41 added.
The largest buyer was Susquehanna International Group, adding an estimated $875K. The largest seller was State Street, cutting an estimated $12.4M.
- 136 institutional investors held Synergy Pharmaceuticals, Inc Common Stock (SGYP) as of Q2 2018, down from 147 in Q1 2018.
- Funds reported $170M of Synergy Pharmaceuticals, Inc Common Stock stock for Q2 2018, down 16% quarter-over-quarter.
- 16 funds opened new Synergy Pharmaceuticals, Inc Common Stock positions in Q2 2018 and 26 closed out, a net change of -10 holders.
- The largest Synergy Pharmaceuticals, Inc Common Stock buyer in Q2 2018 was Susquehanna International Group, an estimated $875K added.
- The largest Synergy Pharmaceuticals, Inc Common Stock seller in Q2 2018 was State Street, an estimated $12.4M sold.
Based on aggregated 13F filings for Q2 2018.